Abstract:The burden of sepsis as a leading cause of global morbidity and mortality is well documented. Sepsis results in high resource utilization and increasing healthcare costs often leaving survivors with life-long disabilities. Numerous novel treatment modalities have often failed in clinical trials in part, because of the heterogeneity of the disease process. These failures have highlighted the critical role that sepsis prevention and early detection play in treatment. Early recognition and prompt initiation of treatment offers the opportunity to intervene before multiple organ system failure commences. Research in the adult patient realm has made great strides with consensus definitions and work to identify biomarkers. In other areas of adult-focused research, emerging technologies have allowed for targeted therapeutics offering "precision" (or "personalized") medicine. As with many areas of medicine, research benefiting our most vulnerable patients, namely neonates and children, has lagged that of adult populations. Unfortunately, newborns and children bear a large share of the sepsis burden especially regarding mortality. 1,2 In this issue of Pediatric Research , Dr. Wang and colleagues have published their manuscript titled "Elevated Total Bile Acid Levels as an Independent Predictor of Mortality in Pediatric Sepsis". 3 In this retrospective analysis, the authors managed to perform a case-control study with 702 septic children (538 survivors and 164 non-survivors) admitted to a single pediatric intensive care unit (PICU) over a 5-year period. Importantly, the authors included an additional 269 non-infected controls that certainly strengthens the study. The authors conclude that serum total bile acids (TBA) appear to be an effective independent biomarker for predicting mortality in children with sepsis. Using a clinical model that identified TBA elevations greater than 17.9 μmol/L was an independent predictor of sepsis mortality with an AUC > 0.842, 54.9% sensitivity, and 96% specificity. Compared to control patients and sepsis survivors, the authors observed greater fluctuations and higher TBA values during hospitalization and at the time of death in the non-survivor cohort. Importantly, we believe that this study provides value by addressing two of the aforementioned challenges of pediatric sepsis – namely defining pediatric sepsis and evaluation for possible biomarkers. Wang et al. utilize the newly developed Phoenix-4 criteria to identify their septic cohort and investigate total bile acid levels as a potential biomarker. Defining sepsis across the age spectrum has been a longstanding challenge. Without clear cut age-specific definitions, treatment of sepsis in pediatric populations has relied heavily on a balance of clinical gestalt and available adult evidence. While numerous biomarkers have been investigated in pediatric sepsis, many lack the desired sensitivity and specificity or have not been widely validated in clinical use.

Role of growth arrest-specific protein 6 in diagnosis and prognosis of sepsis in infants and children

Utility of Cytokines to Predict Neonatal Sepsis.

Pediatric sepsis diagnostic and prognostic biomarkers: pancreatic stone protein, copeptin, and apolipoprotein A-V

Serum Neutrophil Gelatinase-Associated Lipocalin: A Diagnostic Marker in Pediatric Sepsis

Role of CD64 and myeloperoxidase as biomarkers for early diagnosis of sepsis in pediatric intensive care unit

Comparison of the Diagnostic Efficacy of SAA1, HBP, CRP，PCT and Cytokine Profiles for Predicting Infection in Pediatric Febrile Patients

Is There a Role of Presepsin as a Novel Biomarker in Pediatric Sepsis?

Prognostic markers among Egyptian children with sepsis in the Intensive Care Units, Cairo University Hospitals

Value of Thrombomodulin as a Marker for Sepsis in Critically Ill Children

Clinical usefulness of biomarkers for diagnosis and prediction of prognosis in sepsis and septic shock

Admission platelet count and indices as predictors of outcome in children with severe Sepsis: a prospective hospital-based study

Examining bile acids in pediatric sepsis – a step in the right direction

Potential biomarkers used for risk estimation of pediatric sepsis-associated organ dysfunction and immune dysregulation

A six molecule nenonatal serum metabolite biosignature has high neonatal sepsis predictability and resolves upon treatment completion.

Growth arrest-specific protein 6 as a marker of nephritis in systemic sclerosis and juvenile systemic lupus erythematosus patients

Utility of cytokine, adhesion molecule and acute phase proteins in early diagnosis of neonatal sepsis

Cytokine profile as diagnostic and prognostic factor in neonatal sepsis

Relation of Procollagen Type III Amino Terminal Propeptide Level to Sepsis Severity in Pediatrics

The Role of Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Early Indicator of Mortality in Pediatric Septic Shock

LGALS3BP: A Potential Plasma Biomarker Associated with Diagnosis and Prognosis in Patients with Sepsis

A Three-Protein Panel to Support the Diagnosis of Sepsis in Children